CD5 (CD5 Molecule)

In summary, this study illustrates that neoplastic T cells can show an NK-like immunophenotype. Features useful for supporting T-lineage in this context include cytoplasmic CD3 expression assessed using a T-cell-specific CD3 antibody, clonal TCR gene rearrangement, BCL11B expression, and detection of TCRαβ, TCRγδ, or TRBC by immunohistochemistry.

pseudo-RT is a reversible event, and awareness of its characteristic features is essential to prevent overtreatment.

Immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) was commenced under mechanical ventilation. A thorough diagnostic workup followed by prompt initiation of immunochemotherapy can arrest pleural output, enable extubation, and be lifesaving. Clinicians should recognize that MCL rarely presents with persistent massive pleural effusions.

P3, N=635, Active, not recruiting, Acerta Pharma BV | Trial completion date: Oct 2025 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Feb 2027

This case illustrates that SMZL, although rare, should be included in the differential diagnosis of persistent chylous ascites. A comprehensive diagnostic approach combining imaging, bone marrow biopsy, and flow cytometry is essential to establish a timely diagnosis and guide appropriate management, especially in elderly patients.

Grade 3A FL is characterized by marked clinical and biological heterogeneity. Our findings indicate that Ki-67 expression serves as a valuable prognostic marker that can inform therapeutic decision-making in patients with grade 3A FL. The proposed model integrating Ki-67 and clinical variables enhances PFS prediction and supports individualized treatment strategies for these patients.

Fraction-specific analyses showed stronger induction of IL-23R and IL-23R complex expression in PF compared with RF. These findings identify an intraclonal bias toward IL-23 responsiveness in the CLL cells with a phenotype of recently divided, tissue-emigrated cells and suggest the IL-23/IL-23R axis as a potential therapeutic target.

We analyzed the T-ALL microenvironment from 40 T-ALL cases treated on the AALL0434 clinical trial and identified a subpopulation of bone-marrow-enriched CCR4+ FOXP3+ T-regulatory cells which express immune checkpoints (PD-1 and TIGIT) and could be targeted with anti-CCR4 therapy. Lastly, we describe the preclinical efficacy of an anti-CCR4 CAR-T in in vitro and in vivo models, paving the way for future translational efforts in chemotherapy refractory T-ALL.

Immunohistochemistry showed diffuse positivity for CD56, chromogranin A, synaptophysin, and insulinoma-associated protein 1; a Ki-67 index of about 20%; negativity for CD5, CD117 (c-KIT), p63 (TP63), CK5/6, and CD20; and the absence of TdT/CD99-positive immature T cells, supporting a diagnosis of thymic atypical carcinoid. This case highlights the complementary value of imprint cytology and an appropriate immunohistochemical panel, in addition to frozen sections, in avoiding misclassification of tNENs as type A thymoma.

NGS revealed that a common progenitor cell with BCL2-IgH translocation and mutations in TP53, KMT2A, KMT2C, and KMT2D gave rise to two distinct subclones: one (CD5 + CD23+CD200+) CLL driven by mutations in TNFAIP3 and BCORL1, and the other (CD5-CD23-CD200-) driven by mutations in EP300, NOTCH1, and BCL2. This case highlights the significance of clonal heterogeneity in CLL and underscores the crucial role of MFC, flow sorting, and molecular genetics in diagnosing and understanding the complex evolution of this disease.

Here, we report atypical clinicopathological features observed in the case of CEL. These findings have potential biological, diagnostic, and prognostic relevance, emphasizing the need for further studies to elucidate their clinical significance and to expand the understanding of this disease.

P2, N=120, Recruiting, Mayo Clinic | Trial primary completion date: Oct 2030 --> Mar 2027